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Extending the platelet shelf life and enhancing product safety may be achieved by combining 
cryopreservation and pathogen inactivation (PI). Although studied individually, limited 
investigations into combining these treatments has been performed. The aim of this study was 
to investigate the effect of PI-treating platelets prior to cryopreservation on in vitro platelet 
quality and function.  
Study Design and Methods: 
ABO-matched buffy-coat derived platelets in platelet additive solution (SSP+; Macopharma) 
were pooled and split to form matched pairs (n=8). One unit remained untreated and the other 
was treated with the THERAFLEX UV-Platelets System (UVC; Macopharma). For 
cryopreservation, 5-6% dimethylsulfoxide (DMSO) was added to the platelets and they were 
frozen at -80°C. After thawing, untreated cryopreserved platelets (CPPs) and UVC-treated 
CPPs (UVC-CPPs) were resuspended in plasma. In vitro quality was assessed immediately 
post-thaw and after 24 hours of room-temperature storage.  
Results: 
UVC-CPPs had lower in vitro recovery compared to CPPs. By flow cytometry, platelets 
demonstrated a similar abundance of GPIX (CD42a), GPIIb (CD41a), and GPIbα (CD42b-
HIP1), while the activation of GPIIb/IIIa (PAC-1) was increased in UVC-CPPs compared to 
CPPs. UVC-CPPs demonstrated greater phosphatidylserine exposure (annexin-V) and 
microparticle shedding, but similar P-selectin (CD62P) abundance compared to CPPs. UVC-
CPPs displayed similar functionality to CPPs when assessed using aggregometry, 
thromboelastography (TEG) and thrombin generation.  
Conclusion: 
This study demonstrates the feasibility of cryopreserving UVC-PI treated platelet products. 
UVC-PI treatment may increase the susceptibility of platelets to damage caused during 
cryopreservation, but this is more pronounced during post-thaw storage at room-temperature.  




Cryopreservation of platelets at -80 °C with dimethylsulfoxide (DMSO) allows a significant 
extension of shelf life from five days to at least two years.1,2 Over the past decade, 
cryopreserved platelets (CPPs) have become more widely investigated in research and 
clinical practice.3 While the extension of shelf life afforded by cryopreservation addresses a 
major issue associated with conventional platelet storage, improvements to product safety 
could be made through the use of pathogen inactivation (PI).  
Currently, three PI technologies are available for the treatment of platelet products: 
THERAFLEX UV-Platelets System (UVC-PI; Macopharma, Mouvaux, France), INTERCEPT 
Blood System (INTERCEPT; Cerus, Concord, CA, USA), and Mirasol Pathogen Reduction 
Technology System (Mirasol; Terumo BCT, Lakewood, CO, USA). 
The UVC-PI system utilizes UVC light in combination with strong agitation to form cyclobutane 
pyrimidines and pyrimidine pyrimidone dimers.4,5 This inhibits nucleic acid elongation during 
transcription, preventing pathogen replication.4,5 The UVC-PI system effectively inactivates a 
broad range of bacterial, viral and parasitic species,6-8 although it has limited efficacy for 
inactivation of HIV and bacterial spores.9,10 While not yet approved for clinical use, transfused 
autologous UVC-PI treated platelets have a similar circulation time to untreated platelets.11 A 
stage III clinical trial is currently underway investigating platelets treated with the UVC-PI 
system (EudraCT 2015-001035-20). 
Both cryopreservation and UVC-PI treatment result in phenotypic alterations when compared 
to conventionally stored platelets. For CPPs, these alterations are characteristic of platelet 
activation and/or damage, as evidenced by phosphatidylserine externalization, microparticle 
shedding, and granule release.12-14 The changes induced by UVC-PI treatment are more in 
line with an acceleration of the platelet storage lesion, including an increased abundance of 
P-selectin and phosphatidylserine, and activation of the GPIIb/IIIa receptor.5,15,16 Glycolytic 
metabolism also occurs more rapidly during the latter part of storage in UVC-PI treated 
platelets, leading to a fall in pH,10,17 although still within component specifications (pH >6.4).18 
Importantly, several key platelet receptors, including GPIbα and GPIX, are similar in 
abundance to untreated platelets15,17,19 and platelet function appears to be unchanged, as 
measured by thromboelastography.15,20 Therefore, while combining PI treatment and 
cryopreservation may enhance product safety, it is important that the combination of these 
processes does not result in further damage.  
PI treatment of platelet products prior to cryopreservation is a relatively new concept. One 
study has investigated the treatment of platelets with the INTERCEPT system prior to 
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cryopreservation, revealing a similar in vitro phenotype and functionality compared to 
untreated CPPs following thawing.21 Thus, combining PI treatment and cryopreservation 
appears to be feasible. However, it is well established that each PI system has different effects 
on platelet quality and function,9,22,23 thus necessitating an investigation of each PI system in 
this context. Therefore, the aim of this study was to characterize the effects of UVC-PI 
treatment of platelets in additive solution prior to cryopreservation on post-thaw in vitro platelet 
quality and function.  
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Methods and Materials 
Study Design 
This study had ethics approval from the Australian Red Cross Blood Service Ethics 
Committee. All donations were collected from eligible, voluntary donors, in accordance with 
Blood Service guidelines.  
Pathogen inactivation and cryopreservation  
Platelet concentrates were prepared in platelet additive solution (SSP+; Macopharma) from 
four buffy coats, as previously described.24 On day 1, two platelet units were pooled and split 
to form matched pairs (n=8). Within 4 hours of platelet manufacture, UVC-PI treatment was 
performed. All platelet units were transferred to an illumination kit (Macopharma) via sterile 
connection, but only the UVC assigned units were treated with the THERAFLEX UV-Platelets 
System, according to the manufacturer’s instructions.15 The platelets were then transferred to 
the associated storage bag.  
Platelets were frozen immediately after UVC-PI treatment. For platelet cryopreservation, 
approximately 100 mL of 27 % wt/vol DMSO/0.9 % saline (Sypharma Pty. Ltd, Dandenong, 
VIC, Australia) was added to the platelet units to achieve a final concentration of 5-6% (v/v). 
Platelets were transferred to a 450 mL polyvinylchloride platelet storage bag (Macopharma) 
and were frozen at -80 °C, as previously described.24 The untreated cryopreserved units are 
referred to herein as CPPs, and the UVC-PI-treated cryopreserved units are referred to as 
UVC-CPPs.  
Thawed CPPs and UVC-CPPs were reconstituted in paired, freshly thawed whole blood-
derived plasma (275 ± 10 mL). Two plasma units were thawed in a 37 °C water bath, before 
being pooled and split to form a matched pair. Matched platelet units (CPP and UVC-CPP) 
were then thawed in a 37 °C water bath, until they reached 30 °C (5 minutes), then sterile 
welded to a unit of thawed plasma. The plasma was added to the platelet unit and allowed to 
flow in by gravity, during which the platelets were gently mixed to facilitate resuspension. 
Platelet units were sampled, then rested at room-temperature for one hour following 
resuspension, before storage on a platelet agitator (Helmer Inc., Noblesville, IN, USA).  
Laboratory analysis 
Platelet samples (5 mL) were taken from the pooled unit via sterile transfer into an associated 
bag prior to UVC treatment and before freezing to determine platelet count and plasma 
carryover. Following thawing, platelet samples (15 mL) were aseptically removed immediately 
after thawing and reconstitution (post-thaw) and after 24 hours of room-temperature storage 
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(post-storage). At the time of sample removal, all platelet units were investigated visually for 
the presence of swirling and aggregates.  
Platelet counts were measured using an automated hematology analyzer (CELL-DYN 
Emerald, Abbott Diagnostics, IL, USA). The platelet count was used to determine platelet 
recovery following cryopreservation and to perform dilutions allowing for comparisons 
between CPPs and UVC-CPPs.  
Platelet supernatant was prepared by sequential centrifugation at 1,600 x g for 20 minutes 
followed by 12,000 x g for 5 minutes at room-temperature (20-24°C), as previously 
described.14 Supernatants were stored at -80°C until tested. 
The pH of platelet components was measured using a pH meter at room temperature (20-24 
°C) immediately following sampling (Seven Excellence Multiparameter; Mettler Toledo, OH, 
USA). The glucose and lactate concentration were measured from the platelet supernatant, 
as previously described.25  
The platelet phenotype was characterized by flow cytometry. Platelets (3 x 106 in Tyrode’s 
buffer) were labelled for 20 minutes in the dark with the following antibodies CD41a-PE, 
CD42a-PE, CD42b-HIP1-PE, PAC-1-FITC, CD62P-PE (all obtained from BD Biosciences, 
San Jose, CA, USA), CD42b-AN51-PE (Dako, Glostrup, Denmark), or GPVI-eFluor660 
(eBioscience Inc., San Diego, CA, USA). The abundance of surface bound fibrinogen was 
measured by staining platelets (5 x 105 in Tyrode’s buffer) with anti-fibrinogen-FITC (Abcam, 
Cambridge, UK) in the dark for 20 minutes. Phosphatidylserine externalization was analyzed 
by staining platelets (1 x 106 in annexin-V binding buffer; BioLegend, San Diego, CA, USA) 
with annexin-V-FITC (Biolegend) in the dark for 15 minutes. Platelets were diluted in 1 mL of 
Tyrode’s buffer or annexin-V binding buffer and were measured by flow cytometry 
(FACSCanto II, Becton Dickinson, Franklin Lakes, NJ, USA), with a total of 10,000 events 
collected. The platelet population was established based on FSC and SSC properties and 
gating for positive fluorescence was determined using relevant isotype controls (IgG1-
eFluor660 (eBioscience), IgM-FITC (BD Biosciences), IgG-FITC and IgG1-PE (BioLegend)). 
The median fluorescence intensity (MFI) or percentage of positive events was reported, as 
indicated. 
The absolute number of microparticles was determined by flow cytometry using TruCount 
tubes (BD Biosciences), as previously described.13 Platelet microparticles were defined as 
events less than 1.0 µm and identified as staining positive for CD61-APC (Dako) and annexin-
V-FITC (BioLegend). The distribution of particles in the platelet component was assessed by 
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dynamic light scattering technology (ThromboLUX system and ThromboSight software, 
Version 3.11, LightIntegra Technology, Vancouver, BC, Canada).  
The concentration of soluble CD62P (sCD62P), RANTES, PDGF-AB, PF4, and NAP2 (as a 
measure of β-thromboglobulin) were measured from the platelet supernatant using 
commercially available ELISA kits, according to the manufacturer’s instructions (R&D Systems 
Inc., Minneapolis, MN, USA). Platelet supernatant samples were diluted in reagent diluent 
(R&D Systems) in a range of 1:50-1:10000, depending on the cytokine being tested. All 
samples were tested in triplicate against a standard curve and absorbance at 450 nm was 
measured using a plate reader (VARIOSKAN LUX platform, version 5.0.0.42, Thermo Fisher 
Scientific).  
Aggregation was assessed using light transmission aggregometry (Helena Laboratories, 
Beaumont, TX, USA). Platelets were diluted to 300 x 109/L in freshly thawed plasma and 
stimulated with 20 µmol/L adenosine diphosphate (ADP; Sigma, St Louis, MO, USA) or 10 
µg/mL collagen (Helena Laboratories) for 5 minutes following agonist addition. All samples 
were analyzed in duplicate and the average maximal aggregation (%) was reported.  
The platelet clotting potential was measured using a thromboelastogram (TEG 5000; 
Haemoscope Corporation, Niles, IL, USA), as previously reported.26 Platelets were diluted to 
200 x 109/L in freshly thawed plasma and activated with kaolin and calcium chloride prior to 
application of sample to a plain cup. The samples were run for approximately 60 minutes at 
37 °C and the following variables were recorded: R-time (time to clot initiation; min), K-time 
(speed of clot formation; min), maximum amplitude (MA; clot strength; mm), and α-angle (clot 
growth; degrees). 
Thrombin generation was measured using a Calibrated Automated Thrombogram (CAT; 
Thrombinscope BV, Maastricht, The Netherlands). Platelets were diluted to 300 x 109/L in 
freshly thawed plasma and thrombin generation was initiated using PRP reagent (1 pM tissue 
factor; Thrombinscope BV), as previously published.27 All samples were analyzed in triplicate 
and the following variables were recorded: lag time (min), endogenous thrombin potential 
(ETP; nM/min), peak (nM), and time to peak (min). 
Statistical Analysis 
The data were analyzed using GraphPad Prism 7.03 (GraphPad Software Inc.; La Jolla, CA, 
USA) and results are expressed as mean ± standard deviation (SD). Repeated measures two 
way ANOVA with post-hoc Bonferroni multiple comparisons test was used to assess 
differences between CPPs and UVC-CPPs after thawing and storage. Linear regression with 
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Pearson’s correlation (r value) was performed to assess relationships between parameters. A 




UVC-CPPs display reduced platelet recovery  
All platelet units used in this study met targeted specifications for UVC-PI treatment (Table 
1).15 Following cryopreservation, the recovery of all CPP units was above the minimum 
acceptable recovery (>40%) specified by the Council of Europe18 (Table 2). However, UVC-
CPP units had a lower recovery than untreated CPPs (Table 2). The mean platelet volume 
(MPV) was similar between groups (Table 2). Notably, all UVC-CPP units developed 
significant aggregates within 1 hour post-thaw that were persistent during storage, compared 
with only one CPP unit, which developed minor aggregates that dissipated before the 24 hour 
sampling point. Platelet swirl was absent immediately after thawing, however, it was present 
at the 24 hour post thaw sampling time point in both CPPs and UVC-CPPs.  
UVC-PI treatment did not increase glycolysis during post-thaw storage, with all units having 
similar glucose and lactate concentrations (Table 2). Further, the rate of glucose consumption 
and lactate production over the storage period was similar to that of previously published 
results (data not shown).12 Although the pH decreased during storage (Table 2), it did not differ 
between groups and remained within an acceptable range (pH>6.4).18  
UVC-CPPs have an altered surface phenotype  
The abundance of GPIX (CD42a) on platelets was similar between groups immediately after 
thawing and following storage (Figure 1A). GPVI expression was low on CPPs and UVC-CPPs 
post-thaw but was re-expressed during subsequent storage, although to a lesser extent on 
UVC-CPPs (Figure 1B). A similar abundance of GPIbα (HIP1) was present on CPPs and UVC-
CPPs following thawing, which increased in both groups following storage (Figure 1C). 
Interestingly, the conformation of GPIbα was altered on CPPs and UVC-CPPs, as determined 
by CD42b-AN51 binding, where a reduction in AN51 binding indicates GPIbα clustering and 
activation.28 AN51 binding was low but similar between CPPs and UVC-CPPs following 
thawing (Figure 1D), and increased during post-thaw storage. The abundance of resting 
GPIIb/IIIa (CD41a) was not altered between CPPs and UVC-CPPs (Figure 1E). However, 
greater GPIIb/IIIa activation was detected on UVC-CPPs, by PAC-1 binding, which increased 
approximately 3-fold during storage (Figure 1F). PAC-1 binding correlated with an increase in 
fibrinogen bound to the platelets after thawing and storage (Figure 1G), where the greatest 
amount of fibrinogen binding was observed on UVC-CPPs following storage.  
The proportion of platelets expressing P-selectin increased during storage to a similar extent 
in both groups (CD62P; Figure 2A). In contrast, the proportion of UVC-CPPs binding annexin 
V was higher when compared to CPPs post-thaw and post-storage (Figure 2B). UVC-CPP 
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units contained a higher concentration of microparticles than CPP units (Figure 2C). However, 
the concentration of microparticles declined during storage resulting in minimal differences 
between the groups (Figure 2C). The post-thaw particle content of CPPs and UVC-CPPs was 
also measured using dynamic light scattering (Figure 2D and 2E). Consistent with the flow 
cytometry data, UVC-CPP units contained a higher proportion of gated microparticles (CPP: 
24.3 ± 7.8 %; UVC-CPP: 35.6 ± 6.1 %; p=0.0020) than untreated CPPs.  
Supernatant cytokine concentration (ng/mL) after thawing was similar in the two groups (data 
not shown). However, given the lower platelet count in the UVC-CPP units, the results were 
presented as the concentration of cytokine per platelet (Table 3). While there was a trend for 
increased release of cytokines in the UVC-CPPs, the difference was not statistically 
significant.  
UVC-CPPs retain similar functionality to CPPs 
Platelet aggregometry was performed to assess the functionality of CPPs. Interestingly, 
although low, UVC-CPPs were able to aggregate in the absence of agonist stimulation (UVC-
CPP: 2.58 ± 1.32%), which was not detectable in untreated CPPs (0.55 ± 0.46%; p=0.0006). 
The basal aggregation level was moderately associated with the abundance of activated 
GPIIb/IIIa (PAC-1) (r=0.5889; p=0.0025). UVC-CPPs had higher ADP-induced aggregation at 
both time points (Figure 3A); while collagen-induced aggregation was similar in both groups 
immediately after thawing (Figure 3B). Interestingly, CPPs demonstrated a loss of ADP- and 
collagen-induced aggregation during storage, whilst the UVC-CPPs maintained equivalent 
aggregation responses to those measured immediately after thawing (Figure 3A and 3B).  
The hemostatic potential of UVC-CPPs was assessed by TEG and thrombin generation. Using 
TEG, the time to clot formation (R time; Figure 3C) and clot strength (maximum amplitude, 
MA; Figure 3D) was not affected by UVC-treatment. Notably, increasing clot strength was 
associated with a higher abundance of GPIbα (CD42b HIP1; Figure 3E) and GPVI (Figure 
3F). The kinetics of clot development (α-angle and K-time) were not affected by UVC-PI 
treatment and were similar to CPPs (data not shown). The ability of platelets to generate 
thrombin was similar between groups, with UVC-CPPs generating a similar amount of 




This study examined the effect of combining UVC-PI and cryopreservation on platelet in vitro 
quality and function. While cryopreservation and UVC-PI individually address challenges 
associated with conventional platelet storage, combining such techniques has the potential to 
improve the safety profile of CPPs. Although the results confirm that CPPs are activated, the 
combination of UVC-PI and cryopreservation imparts small additional alterations to the CPP 
phenotype. However, these, and other effects, became more pronounced during post-thaw 
storage. Importantly, their in vitro functionality remains similar.  
The recovery of UVC-CPPs was significantly lower than CPPs after cryopreservation. This 
reduced recovery in UVC-CPPs was not a result of product loss during transfer through the 
UVC-PI illumination kit, as both untreated and UVC-PI treated platelets underwent this 
process. The reduction in platelet count may have arisen due to aggregate formation in UVC-
CPP units after thawing.29 The formation of aggregates during storage is undesirable as it 
reduces the platelet concentration, may reduce in vitro platelet quality, and accelerate the 
platelet storage lesion.30,31 It would be of interest to determine whether modifying the thawing 
process could reduce or prevent aggregate formation.  
Activation of GPIIb/IIIa on conventionally stored UVC-PI platelets occurs due to a reduction in 
disulphide bonds,29 leading to a conformational change and increased PAC-1 binding, 
whereas a similar level of resting GPIIb/IIIa is maintained compared to untreated platelets.15 
The data presented here also reflects this. GPIIb/IIIa is responsible for mediating platelet 
aggregation through fibrinogen crosslinking.32 Activation of GPIIb/IIIa may also be responsible 
for the increased in vitro aggregation responses seen with UVC-CPPs. Interestingly, the 
increased PAC-1 staining observed with UVC-CPPs correlated with the increased basal 
aggregation level and fibrinogen binding. Similar results have previously been described in 
liquid stored THERAFLEX and Mirasol-treated platelets.33,34 Therefore, aggregate formation 
may be facilitated by the increased abundance of activated GPIIb/IIIa, and subsequent binding 
of fibrinogen from the plasma used for reconstitution.35,36 Substituting plasma, either partially 
or completely, with an alternative reconstitution media, such as a platelet additive solution or 
saline, may reduce or eliminate aggregate formation36 while still preserving platelet quality.37,38  
UVC-PI treatment prior to cryopreservation did not adversely alter basal expression of platelet 
glycoproteins immediately after thawing. However, small changes became evident after post-
thaw storage. The increased abundance of platelet receptors in both CPPs and UVC-CPPs 
following 24 hours of post-thaw storage suggests that certain receptors may be internalized 
as a result of the cryopreservation process and are later re-expressed during post-thaw 
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storage. Alternatively, de novo protein synthesis of these platelet receptors may be 
occurring.39 UVC-PI treatment may damage the platelet mRNA, as has been shown with other 
PI systems,40 or the ability of CPPs to synthesize proteins, resulting in altered expression of 
platelet receptors following 24 hours of post-thaw storage. While receptor expression 
improved on thawed platelets over storage, UVC-CPPs did not recover to the same extent as 
untreated CPPs. CPPs and UVC-CPPs demonstrated recovery of GPIbα during storage, and 
a reduction in the ‘clustered’ conformation of this receptor, which may be due to GPIbα re-
expression of the receptor in a resting state following shedding. This reduction is interesting 
given that clustering of GPIbα is linked to enhanced clearance upon transfusion.41 Similarly, 
GPVI, a primary receptor for collagen-induced platelet activation, was also re-expressed 
during platelet storage. This difference appeared to have little impact on collagen-induced 
platelet aggregation, suggesting some redundancy of GPVI signalling or that alternative 
collagen-binding receptors may be retained and functional.42 Notably, the increased 
abundance of GPIbα (HIP1) and GPVI was positively associated with an increase in the 
maximum amplitude as measured by TEG. This highlights the importance of these receptors 
in platelet adhesion and thrombus formation.43 
Platelet activation occurs during storage (liquid and post-thaw) resulting in the release of 
platelet granules with concomitant accumulation of cytokines within the platelet product.44,45 
Further, for CPPs, the plasma used to resuspend platelets may contribute to the total amount 
of cytokines present within each platelet unit. However, the paired CPPs and UVC-CPPs were 
resuspended in pooled units of plasma. Therefore, any variations in the cytokine profile are a 
consequence of UVC-PI treatment, the cryopreservation process, or the combination of these 
two processes.  
The externalization of phosphatidylserine on platelets and microparticles is believed to play 
an important role in the overall functionality of CPPs.13,26,46 Phosphatidylserine provides a 
catalytic site for assembly of coagulation factors, ultimately leading to thrombin generation.47 
Although UVC-CPPs contained a larger proportion of platelets with externalized 
phosphatidylserine and more microparticles, this did not translate to increased thrombin 
generation. It may be that such a significant proportion of CPPs express phosphatidylserine 
that maximal thrombin generation had been reached. Therefore, the increased 
phosphatidylserine exposure observed in UVC-CPPs was not able to potentiate this further. 
Overall, the functionality of CPPs and UVC-CPPs was similar as measured by numerous 
assays.  
The cryopreservation protocol used in our institute is classified as an ‘open’ system, which 
limits the post-thaw shelf life of CPPs to 6 hours.3,48 However, DMSO products are now 
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available in sterile bags, which would allow for aseptic addition of the cryoprotectant. The 
addition of DMSO to the platelet product using a closed system in combination with PI-
treatment of platelets prior to cryopreservation would ideally translate to an extension of the 
post-thaw shelf life beyond 6 hours. Data presented here demonstrate that functional aspects 
of UVC-CPPs are maintained after 24 hours of post-thaw storage. However, the phenotypical 
alterations observed following post-thaw storage of UVC-CPPs may limit the shelf-life. A 
greater understanding of the impact of UVC-PI is required before an appropriate post-thaw 
shelf life of UVC-CPPs could be established.  
This study focused on the post-thaw analysis of UVC-CPPs compared to CPPs, meaning 
some limitations in regards to the study design were observed. A direct comparison of liquid 
preserved platelets with or without UVC-PI treatment prior to freezing was not conducted due 
to the well-established differences between liquid-stored platelets and CPPs.12-14,49 Further, 
given the minimal time between treatment and freezing, and the fact that alterations induced 
by UVC-PI treatment appear following storage rather than immediately following 
treatment,15,16,19 no immediate UVC-PI induced changes were expected. Platelet components 
undergoing UVC-PI treatment are required to meet certain component specifications prior to 
treatment, to minimize damage. The specifications targeted in this study were different to 
those validated in Europe,50 and the starting parameters of the platelet units were at the 
extremes of the targeted treatment specifications, suggesting that the results likely represent 
the worst case scenario. However, previous data demonstrate that platelet components 
meeting the specifications used in this study are suitable for UVC-PI treatment followed by 
conventional storage at 20-24 °C.15 The results are also in line with recent reports of 
INTERCEPT treated CPPs, which demonstrate minimal alterations to the CPP phenotype.21 
Additionally, if the rationale for PI-treating platelets is to improve product safety, then PI-
treatment of the plasma used as the resuspension medium should also be considered.  
To summarize, we have investigated the impact of UVC-PI on CPP products on in vitro quality 
and function. Several differences were identified between CPPs and UVC-CPPs. The 
combination of UVC-PI treatment followed by cryopreservation, thawing, and resuspension in 
plasma resulted in the formation of persistent aggregates. However, most other in vitro quality 
and functional parameters were not immediately impacted, although more significant changes 
developed during post-thaw storage. Clinical studies will be required to determine whether the 
observed differences translate to clinically relevant effects in the overall context of 




We are thankful to Macopharma for suppling the illuminator and disposables for this project, 
and acknowledge Frank Tolksdorf and Chryslain Sumian from Macopharma for critically 
reviewing the manuscript. LW gratefully acknowledges the Alexander Steele Young Memorial 
Lions Foundation for their generosity in supporting her PhD studies.  
  
Author contributions 
LJ, LW and DCM conceived and designed the study; LJ and LW performed the experiments, 
analyzed the data and drafted the manuscript; all authors contributed to writing the paper, 











Volume (mL) 325-375 364.2 ± 10.0 
Platelet concentration (x109/L) 700-1400 819.6 ± 63.3 
Plasma carryover (%) 25-35 27.9 ± 2.6 





Table 2. Platelet recovery and metabolic parameters of cryopreserved platelets 
 Post-Thaw Post-Storage  
 CPP UVC-CPP CPP UVC-CPP p value 
Recovery (%) 69.66 ± 2.44 61.45 ± 3.00* 47.39 ± 3.37 44.08 ± 2.55 <0.0001 
Platelets (x 109/L) 704.38 ± 74.64 620.25 ± 57.51 494.38 ± 54.23 459.25 ± 46.29 0.0428 
MPV (fL) 5.16 ± 0.14 5.15 ± 0.12 5.64 ± 0.14 5.89 ± 0.23 0.0572 
Glucose (mmol/L) 19.05 ± 2.83 17.27 ± 2.10 18.37 ± 2.26 17.03 ± 2.15 0.6874 
Lactate (mmol/L) 5.61 ± 1.07 5.70 ± 1.11 8.42 ± 1.18 8.56 ± 1.34 0.8432 
pH (20-24 °C) 7.24 ± 0.04 7.29 ± 0.07 7.18 ± 0.06 7.21 ± 0.08 0.1680 
Post-thaw = immediately following thawing; Post-storage = 24 hours following thawing; CPP= cryopreserved platelet; UVC-CPP = UVC pathogen 
inactivated cryopreserved platelet; MPV = mean platelet volume 
Values shown as mean ± SD, n=8 in each group  
p values were obtained using a repeated measures ANOVA to compare treatment at each time point. * indicates p<0.01 compared to CPP at the 
same time point   
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Table 3. Cytokine release from cryopreserved platelets  
  Post-Thaw Post-Storage  
 Cytokine CPP UVC-CPP CPP UVC-CPP p value 
sCD62P (µg/1011 platelets) 9.61 ± 1.15 10.12 ± 1.38 25.43 ± 3.08 27.26 ± 3.40 0.2576 
RANTES (µg/1011 platelets) 9.08 ± 1.61 10.04 ± 1.85 23.43 ± 3.82 24.92 ± 3.13 0.2914 
PDGF-AB (µg/1011 platelets) 2.14 ± 0.58 2.27 ± 0.39 3.57 ± 0.68 3.79 ± 0.80 0.5623 
PF4 (µg/1011 platelets) 897.31 ± 113.41 968.85 ± 91.74 1667.41 ± 178.28 1833.41 ± 356.29 0.7433 
NAP2 (µg/1011 platelets) 804.35 ± 112.78 896.32 ± 92.47 1436.37 ± 249.74 1737.21 ± 207.87 0.0176 
Post-thaw = immediately following thawing; Post-storage = 24 hours following thawing; CPP= cryopreserved platelet; UVC-CPP = UVC pathogen 
inactivated cryopreserved platelet 
Values shown as mean ± SD, n=8 in each group  






Figure 1. Pathogen inactivation alters glycoprotein expression of platelets following 
cryopreservation.  
Platelets were either untreated or pathogen inactivated (UVC-PI) prior to cryopreservation. 
Cryopreserved platelets (CPP) and pathogen inactivated CPPs (UVC-CPP) were sampled 
immediately following thawing (post-thaw) and 24 hours following thawing (post-storage). 
Platelets were stained with (A) CD42a-PE, (B) GPVI-eFluor660, (C) CD42b-HIP1-PE, (D) 
CD42b-AN51-PE, (E) CD41a-PE, or (F) PAC-1-FITC and the median fluorescence intensity 
(MFI) was measured by flow cytometry. (G) Scatter plot depicting the correlation between 
bound fibrinogen and activated GPIIb/IIIa (PAC-1). Data shown as mean ± SD (error bars) or 
as individual data points (scatter plots), with n=8 in each group. * indicates p<0.01 compared 
to CPPs at that time point.  
 
Figure 2. Pathogen inactivation increases the activation status of platelets following 
cryopreservation.  
Platelets were either untreated or pathogen inactivated (UVC-PI) prior to cryopreservation. 
Cryopreserved platelets (CPP) and pathogen inactivated CPPs (UVC-CPP) were sampled 
immediately following thawing (post-thaw) and 24 hours following thawing (post-storage). 
Platelets were stained with (A) CD62P-PE or (B) Annexin V-FITC and the percentage positive 
events was measured by flow cytometry. (C) The absolute number of CD61+/annexin-V+ 
microparticles was enumerated by flow cytometry. Data shown as mean ± SD (error bars), 
with n=8 in each group. * indicates p<0.01 compared to CPPs at that time point. Dynamic light 
scattering was used to assess the particle size of the platelet components, with representative 
traces shown for (D) CPPs and (E) UVC-CPPs immediately post-thaw. The mean size (nm) 
of the populations and the proportion of particles (%) within that population is presented. The 




Figure 3. Pathogen inactivation has minimal impact on platelet function following 
cryopreservation.  
Platelets were either untreated or pathogen inactivated (UVC-PI) prior to cryopreservation. 
Cryopreserved platelets (CPP) and pathogen inactivated CPPs (UVC-CPP) were sampled 
immediately following thawing (post-thaw) and 24 hours following thawing (post-storage). 
Platelet aggregation was measured in response to (A) 20 µmol/L ADP and (B) 10 µg/mL 
collagen. (C) R-time (reaction time; time until clot formation) and (D) the maximum amplitude 
(maximum clot strength) were measured using thromboelastography. Scatter plots depicting 
the correlation between (E) the maximum amplitude and GPIbα (CD42b-HIP1) expression and 
(F) the maximum amplitude and GPVI expression. (G) Peak thrombin and (H) the time to peak 
thrombin formation were measured using a calibrated automated thrombogram. Data shown 
as mean ± SD (error bars) or as individual data points (scatter plot), with n=8 in each group. * 
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